Iterum Therapeutics Q3 2025: ORLYNVAH launch nets $0.4M revenue; cash runway extended to Q2 2026

Iterum Therapeutics plc

2025-Q3 EPS reported -$0.51 revenue$390,000

Net product revenue of $0.4M from ORLYNVAH launch in August 2025; 2026 sales guidance $5M-$15M.
Cash and equivalents $11.0M as of Sep 30, 2025; additional $2.6M raised Oct-Nov 2025 extends runway into Q2 2026.
GAAP net loss $9.0M ($0.81 diluted EPS); non-GAAP net loss $7.3M vs. $6.1M and $4.8M in Q3 2024.
SG&A expenses rose to $6.5M from $1.8M YoY due to commercialization; R&D fell to $1.3M.
Granted patents in China and Mexico covering sulopenem combinations; IDWeek posters presented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.